FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial
By Katherine Hamilton
Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment.
The hold has been lifted for a Phase 2 study of lorigerlimab as a treatment for gynecological cancers.
The FDA placed a hold on the study in February due to safety issues. Four patients experienced safety events, including thrombocytopenia, myocarditis, neutropenia and concurrent septic shock.
During the hold, existing study participants were able to continue receiving the study drug, the clinical-stage biopharmaceutical company said Wednesday. New participants will be enrolled under a revised protocol that includes additional risk mitigation.
Chief Executive Eric Risser said Macrogenics plans to resume enrollment and is on track to provide a mid-year clinical update.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 08, 2026 17:24 ET (21:24 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States